Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 2097-2102

  Perng, Reury Perng ^a   Chen, Yuh Min ^a   Ming Liu, Jacqueline ^a   Tsai, Chun Ming ^a   Lin, Wei Chun ^a   Yang, Kuang Yao ^a   Whang Peng, Jacqueline ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TAIWAN; THROMBOCYTOPENIA; VOMITING;

EID: 0030900495     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.2097     Document Type: Article

References (30)

1. Chen YM: New chemotherapeutic agents for non-small cell lung cancer. Clin Med (ROC) 37:22-25, 1996
2. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
3. Bunn PA Jr: The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 16:10-21, 1989 (suppl 6)
4. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
5. Chevalier TL: Chemotherapy for advanced NSCLC - Will meta-analysis provide the answer? Chest 109:107S-109S, 1996
6. Miller VA, Rigas JR, Grant SC, et al: New chemotherapeutic agents for non-small cell lung cancer. Chest 107:306S-311S, 1995
7. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
8. Martin C, Lund B, Anderson H, et al: Gemcitabine weekly schedule better tolerated than twice weekly schedule. Proc Am Soc Clin Oncol 14: A1376, 1995 (abstr)
9. Srensen JB: Gemcitabine in non-small cell lung cancer. Lung Cancer 12:173-175, 1995 (suppl 1)
10. Cottier B, Gatzemeier U, Shepherd F, et al: A multicenter phase II trial with gemcitabine in non small cell lung cancer (NSCLC). Eur Respir J 7:410, 1994 (suppl 18, abstr)
11. Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
12. Kaye SB: Gemcitabine: Current status of phase I and II trials. J Clin Oncol 12:1527-1531, 1994
13. Gatzemeier U, Shepherd FA, Chevalier TL, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 32A:243-248, 1996
14. Klastersky J, Sculier JP, Ravez P, et al: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 4:1780-1786, 1986
15. Klastersky J, Sculier JP, Bureau G, et al: Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 7:1087-1092, 1989
16. Klastersky J, Sculier JP, Lacroix H, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8:1556-1562, 1990
17. Crino L, Tonato M, Darwish S, et al: A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): A study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 26:52-56, 1990
18. Rosso R, Salvati F, Ardizzoni A, et al: Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Cancer 66:130-134, 1990
19. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland, World Health Organization, 1979
20. Kaasa S, Lund E, Thorud E, et al: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 67:2443-2447, 1991
21. Henwood JM, Brogden RN: Etoposide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39:438-490, 1990
22. Kunitoh H, Watanabe K: Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 12:83-89, 1994
23. Loprinzi CL, Goldberg RM, Su JQ, et al: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12:1126-1129, 1994
24. Robert F, Wheeler RH, Molthrop D, et al: Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer. Am J Clin Oncol 17:383-386, 1994
25. Saito H, Shimokata K, Yamamoto M, et al: Phase II study of a 72-h concurrent continuous infusion of cisplatin and etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 32:134-136, 1993
26. Chen YM, Liu JM, Tsai CM, et al: Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer. J Clin Oncol 14:1743-1744, 1996
27. Testa MA, Simonson DC: Assessment of quality-of-life outcomes. N Engl J Med 334:835-840, 1996
28. Abratt RP, Bezwoda WR, Goedhals L, et al: A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 14:375, 1995 (abstr 1159)
29. Carmichael J, Allerheiligen S, Walling J: A phase I/II study of gemcitabine (GEM) and carboplatin (CBP) in NSCLC. Proc Am Soc Clin Oncol 14:351, 1995 (abstr 1065)
30. Shepherd F, Cormier Y, Evans W, et al: A phase II study of gemcitabine and cisplatin weekly x 3 every 4 weeks in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:380, 1996 (abstr 1135)